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Bramley, Jayne R., Patricia J. Sollars, Gary E. Pickard, and
F. Edward Dudek. 5-HT1B receptor-mediated presynaptic inhibition of GABA release in the suprachiasmatic nucleus. J Neurophysiol 93: 3157–3164, 2005. First published February 16, 2005;
doi:10.1152/jn.00770.2004. The suprachiasmatic nucleus (SCN)
receives a dense serotonergic innervation that modulates photic
input to the SCN via serotonin 1B (5-HT1B) presynaptic receptors
on retinal glutamatergic terminals. However, the majority of
5-HT1B binding sites in the SCN are located on nonretinal terminals and most axonal terminals in the SCN are GABAergic. We
therefore tested the hypothesis that 5-HT1B receptors might also be
located on SCN GABAergic terminals by examining the effects of
the highly selective 5-HT1B receptor agonist CP-93,129 on SCN
miniature inhibitory postsynaptic currents (mIPSCs). Whole cell
patch-clamp recordings of mIPSCs were obtained from rat and
mouse SCN neurons in hypothalamic slices. Using CsCl-containing microelectrodes with QX314, we isolated mPSCs that were
sensitive to the GABAA receptor antagonist, bicuculline. Bath
application of CP-93,129 (1 M) decreased the frequency of
mIPSCs by an average of 22% (n ⫽ 7) in rat SCN neurons and by
an average of 30% (n ⫽ 8) in mouse SCN neurons with no clear
effect on mIPSC amplitude. In mice lacking functional 5-HT1B
receptors, CP-93,129 (1 M) had no clear effect on the frequency
or the amplitude of mIPSCs recorded in any of the cells tested (n ⫽
4). The decrease in the frequency of mIPSCs of SCN neurons
produced by the selective 5-HT1B receptor agonist CP-93,129 is
consistent with the interpretation that 5-HT1B receptors are located
on GABA terminals in the SCN and that 5-HT inhibits GABA
release via a 5-HT1B presynaptic receptor-mediated mechanism.

The suprachiasmatic nucleus (SCN) controls circadian
rhythms and thus functions as the “master clock” of the brain
(Klein et al. 1991). The SCN is composed of numerous
single-cell oscillators (i.e., “clock cells”) that, when synchronized, produce a coordinated circadian output. Modification of
SCN output (i.e., firing rate of SCN neurons) ultimately affects
physiological and behavioral rhythms.
The SCN receives a direct glutamatergic input from the
retina via the retinohypothalamic tract (RHT) that is formed
from axons of retinal ganglion cells (Castel et al. 1993). In
addition, the SCN receives indirect retinal input from retinorecipient neurons of the intergeniculate leaflet (IGL) via the
geniculohypothalamic tract (GHT) (Morin 1994). Both of these
sources of photic information modify SCN output and serve to
entrain the SCN circadian clock to the 24-h environmental
day-night cycle (Hendrickson et al. 1972; Moore and Lenn

1972; Pickard 1982; Pickard et al. 1987). The SCN also
receives one of the densest serotonergic innervations in the
brain arising from ascending projections of serotonin (5-HT)
neurons in the midbrain median raphe nucleus (Meyer-Bernstein and Morin 1996). The terminal fields of retinal, IGL, and
serotonergic afferents are coextensive in the ventral region of
the SCN, suggesting that 5-HT afferents may modify RHT
and/or IGL input to the SCN. Indeed, destruction of 5-HT
afferents to the SCN modifies circadian behavioral responses to
light (Morin and Blanchard 1991; Smale et al. 1990).
The 5-HT receptor subtype(s) in the SCN and their subcellular distribution remain to be fully elucidated. Of the 14 5-HT
receptor subtypes currently described, several have been localized
to the SCN, including the 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C,
5-HT5A, and 5-HT7 receptor subtypes (Belenky and Pickard 2001;
Duncan et al. 1999, 2000; Prosser et al. 1993; Rea and Pickard
2000a; Roca et al. 1993; Smith et al. 2001; Sumner et al. 1992).
5-HT1B receptors are found predominately on axon terminals
within the CNS (Boschert et al. 1994). In the SCN, 5-HT1B
receptors are located on RHT terminals (Belenky and Pickard
2001; Pickard et al. 1999). There is strong evidence that activation
of 5-HT1B receptors in the SCN plays a particularly important role
in modifying photic input (Hayashi et al. 2001; Pickard and Rea
1997; Pickard et al. 1996, 1999; Rea and Pickard 2000b; Shimazoe et al. 2004; Smith et al. 2001). However, most 5-HT1B
receptors in the SCN are located on nonretinal terminals, as
evidenced by the 35% reduction in the number of 5-HT1B
binding sites in the SCN after bilateral enucleation (Manrique
et al. 1999; Pickard et al. 1996). These nonretinal 5-HT1B
receptors might be located on the terminals of other major
afferents to the SCN, such as the 5-HT projection from the
raphe nucleus (O’Connor and Kruk 1992) or the NPY/GABA
projection from the IGL (Manrique et al. 1999). The majority
of axonal boutons in the SCN are GABAergic, and they arise
from the local GABAergic network, which is extensive (Castel
and Morris 2000; Strecker et al. 1997; van den Pol 1986).
Recent studies with 5-HT1B receptor knockout (5-HT1B KO)
mice have shown that the lack of functional 5-HT1B receptors
produces an attenuated response to light (Ogilvie et al. 2004).
If 5-HT1B receptors are located presynaptically on GABA
terminals, the reduced response to light in KO mice may be the
result of increased GABAergic neural activity in the SCN
resulting from the lack of effect of 5-HT on 5-HT1B receptors.
In this study, we tested the hypothesis that 5-HT inhibits
GABA release in the SCN via activation of 5-HT1B presynaptic
receptors on GABA terminals by analyzing the frequency and
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amplitude of GABAA-receptor-mediated miniature inhibitory
postsynaptic currents (mIPSCs). We examined the effects of
the potent and highly selective 5-HT1B receptor agonist CP93,129 on mIPSCs of SCN neurons in hypothalamic slices
obtained from Sprague-Dawley rats and C57BL/6J wild-type
and 5-HT1B KO mice.
METHODS

onist DL-2-amino-5-phosphonopentanoic acid (APV; 50 M), and
tetrodotoxin (TTX; 1 M). Solutions of the GABAA-receptor antagonist bicuculline (30 M) were prepared daily. DNQX and APV were
obtained from RBI/Sigma (Natick, MA) and TTX was obtained from
Alomone Labs. A stock solution of the highly selective 5-HT1B agonist
CP-93,129 (1 mM) was prepared in water and subsequently diluted to
the final concentration (1 M, Tocris Cookson, Ellisville, MO).
RESULTS

Hypothalamic slice preparation

Whole cell patch-clamp recordings

Male Sprague-Dawley rats (Harlan) and C57BL/6J wild-type (Jackson Laboratory, Bar Harbor, ME) and 5-HT1B KO mice on the
C57BL/6 background (in-house breeding and originally provided by
Dr. René Hen, Columbia University) (Saudou et al. 1994) aged
between 4 and 6 wk were maintained under a 12:12 light: dark cycle
with lights on at 07:00 h. Food and water were available ad libitum.
Animals were deeply anesthetized by halothane inhalation and
killed by decapitation at 10:00 –11:00 h. Brains were then rapidly
dissected, blocked in the coronal plane, and immersed in oxygenated
(95% O2-5% CO2), ice-cold artificial cerebrospinal fluid (ACSF)
containing (in mM) 124 NaCl, 24 NaHCO3, 3 KCl, 2 MgSO4, 1.25
NaH2PO4, 2.5 CaCl2, and 10 glucose, pH 7.4. Brain blocks were
glued to the stage of a Vibratome and 300-m-thick coronal slices
containing the bilateral SCN were cut. Slices were placed in a holding
chamber and incubated for 1–2 h in oxygenated ACSF at 36°C before
being transferred into the recording chamber. All experiments were
performed at 12:00 –17:00 h.

Patch-clamp recording
Slices were continuously perfused (2 ml/min) with oxygenated
ACSF (identical to that used in the dissection) and maintained at a
temperature of 35°C. Pipettes were pulled (P-87 Flaming-Brown
pipette puller, Sutter Instruments) from borosilicate glass capillaries
of 1.65-mm OD and 0.45-mm wall thickness (Garner Glass) and filled
with a solution containing (in mM) 130 CsCl, 10 N-2-hydroxyethylpiperazine-N⬘-2-ethanesulfonic acid (HEPES), 1 NaCl, 1CaCl2, 1
MgCl2, 5 ethylene glycol-bis (␤-aminoethyl ether)-N,N,N⬘,N⬘-tetraacetic acid (EGTA), 2 ATP, 0.2 GTP, and 5 QX314, and pH
adjusted to 7.2–7.3 with CsOH. Open resistance was 4 – 6 M⍀. Whole
cell patch-clamp recordings were made using infrared illumination
with differential interference contrast optics (IR-DIC) video microscopy. Seal resistances were typically 1– 4 G⍀, and series resistances
were ⬍20 M⍀. After the whole cell configuration was established,
cells were initially held near the resting membrane potential for 2–5
min to allow equilibration of the extracellular and recording electrode
solutions. Whole cell currents were amplified with an AxopatchMulticlamp 700A amplifier (Axon Instruments) and digitized with a
Digidata 1322 (Axon Instruments). Records were collected and stored
onto a Pentium III PC using the pCLAMP 8.0 software, (Axon
Instruments), and analyzed off-line with Mini-Analysis software (Justin Lee, Synaptosoft). Drug effects were analyzed using the Student’s
t-test. Cumulative plots were compared using the Kolmogorov-Smirnov test (KS-test; 2-tailed). The results of the cumulative plots are
presented as the D value rather than using the P values. The D value
is defined as the maximum value of the absolute difference between
two cumulative distribution functions. Due to the large number of
points in each cumulative plot, a very small difference can lead to a
significant P value (i.e., ⬍0.05), which, when combined with a small
difference in the D value, can be misleading. It was therefore decided
that the most appropriate way to report the results from the cumulative
plots was to use the D value. All results are reported as ⫾SE unless
stated otherwise.
Miniature IPSCs (mIPSCs) were isolated by using the glutamate
AMPA/kainate receptor antagonist, 5,7-dinitroquinoxaline-2,3-dione
(DNQX; 10 M), the N-methyl-D-aspartate (NMDA) receptor antagJ Neurophysiol • VOL

Whole cell patch-clamp recordings were obtained from 7
SCN neurons in coronal hypothalamic slices from rats and 12
SCN neurons from mice (only 1 cell was recorded from each
slice). Cells were voltage-clamped at ⫺60 mV. Resting membrane potentials could not be measured due to the pipette
recording solution containing CsCl and QX314. However, after
establishing the whole cell configuration, a period of 2–5 min
was allowed for the equilibration of intracellular and recording
solutions before recording began. In all recordings, a stable
baseline was achieved, and then the drug was applied followed
by a washout period of ⱖ20 min or for as long as the recording
was adequate. GABAA-receptor-mediated mPSCs were pharmacologically isolated by applying a combination of APV (50
M) and DNQX (10 M) to block NMDA and AMPA/kainate
receptors, respectively, and TTX (1 M) to block sodiummediated action potentials and the postsynaptic currents from
them. All remaining currents could be reversibly suppressed by
the GABAA receptor antagonist bicuculline (30 M), shown in
Fig. 1. Due to the high variance in both the frequency and
amplitude of mIPSCs between individual cells, effects were
best assessed as a percentage of control values. In experiments

FIG. 1. The pharmacological isolation of GABAA-receptor-mediated miniature inhibitory postsynaptic currents (mIPSCs). Top: a 35-min whole cell
record of PSCs from a rat suprachiasmatic nucleus (SCN) neuron. Bottom: 2-s
segments of the recording within the boxed parts are expanded (A–C). A:
combination of both excitatory and inhibitory sPSCs. B: isolation of mIPSCs
by the addition of 2-amino-5-phosphonopentanoic acid (AP5) and 5,7-dinitroquinoxaline-2,3-dione [DNQX; glutamate receptor antagonists to block excitatory postsynaptic currents (EPSCs)] and TTX (blocks sodium-mediated
action potentials and the postsynaptic currents from them). C: all remaining
currents were reversibly suppressed by the GABAA receptor antagonist bicuculline (Bic 30 M). The IPSCs were inward currents due to a high Cl⫺
concentration in the patch pipette. The cell was voltage-clamped at ⫺60 mV.
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FIG. 2. CP-93,129 reduced the frequency but not the amplitude of GABAAreceptor-mediated mIPSCs in the rat SCN. Top: a 20-min recording of
mIPSCs. The slice was bathed in AP5 (50 M), DNQX (10 M), and TTX (1
M). Bottom: periods of 2 s from within the boxed parts are expanded (A–C).
A: control period before application of CP-93,129. All currents were mIPSCs.
B: bath application of CP-93,129 (1 M) reduced the frequency but not the
amplitude of mIPSCs. C: washout of CP-93,129 to baseline levels.

using mice, the investigator was blind concerning the genotype
(i.e., wild-type vs. 5-HT1B KO).
Effects of CP-93,129 application in the rat
CP-93,129 (1 M) was bath applied, and the slices (n ⫽ 7)
were exposed to the 5-HT1B agonist for 4 min (Fig. 2). Data
from dose-dependent responses for CP-93,129 indicate 1 M
to be a maximally effective dose (e.g., Berger and Huynh
2002). In three of the cells tested, mIPSCs showed a decrease
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in frequency; before exposure to CP-93,129, the average frequency of mIPSCs for these three cells was 3.0 ⫾ 2.0 Hz
compared with 1.3 ⫾ 0.6 Hz after exposure to the 5-HT1B
agonist (i.e., a 57% reduction). The mIPSC amplitude was
reduced from 49.2 ⫾ 10.0 pA in the control period to 41.4 ⫾
5.9 pA (i.e., 16%) after application of the agonist. The cumulative plot (Fig. 3C) of mIPSC amplitude from a representative
cell within this group gives a D value of 0.1, representing a
maximal 10% shift between the two data plots at one point.
This indicates a relatively small decrease in mIPSC amplitude,
and the KS test showed that this was not significantly different
(i.e., P ⫽ 0.1). Unlike the effect on frequency, this small effect
on amplitude did not recover, suggesting that it was due to
slight deterioration of the recording rather than an effect of the
agonist. Of the three cells that showed the decrease in frequency in response to CP-93,129, the mIPSC frequency of two
cells recovered completely to control levels in the washout
period, and one recording was lost before complete washout
was achieved. The remaining four cells of the seven tested
showed no clear change in frequency (7.0 ⫾ 5.2 Hz baseline
compared with 6.3 ⫾ 4.7 Hz with 5-HT1B agonist) or amplitude (45.1 ⫾ 2.1 pA compared with 42.4 ⫾ 2.1 pA) of mIPSCs
in response to CP-93,129 application. If we consider all seven
cells tested as a single population, then a conservative calculation is that CP-93,129 caused a 22% reduction in the
frequency of mIPSCs (P ⫽ 0.03, paired t-test), and this
is summarized in Fig. 8A. That the effect of CP-93,129
was predominately if not exclusively on the frequency of
mIPSCs suggests a presynaptic action of the 5-HT1B receptor agonist.
Effects of CP-93,129 application in the wild-type mouse
The same experimental procedure as used for the rat was
followed for the mouse. CP-93,129 (1 M) was bath applied,
and cells were exposed to the 5-HT1B agonist for 4 min. In

FIG. 3. Analysis of mIPSC frequency and amplitude
recorded from a rat SCN neuron. A: the frequency of
mIPSCs was reduced after application of CP-93,129 and
recovered during the washout period. B: the amplitude
histogram shows a decrease in amplitude during the
recording that began before drug application and did not
recover during the washout period; therefore these data
were not interpreted as a drug effect and may have been
caused by gradual deterioration of the recording. Bin
size ⫽ 120 s and error bars represent SE. C: the cumulative plot shows a small apparent decrease (10%) in the
amplitude of mIPSCs after application of CP-93,129, but
this was not a significant difference (P ⫽ 0.1). D: the
amplitude distributions are similar for control and CP93,129 (bin size ⫽ 10 s).
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additional three cells showed a more subtle but still clear effect
of CP-93,129. In these cells, the frequency of mIPSCs in the
control period was 4.8 ⫾ 2.6 Hz and was 3.7 ⫾ 2.1 Hz during
drug application, a 23% reduction in frequency. The frequency
of mIPSCs did not fully recover to control levels in those cells
that showed a more dramatic response to CP-93,129, but there
was a definite trend of increasing mIPSC frequency during the
washout period. The remaining two cells did not show a clear
effect in response to CP-93,129. The cumulative plots of the
eight cells show D values in the range of 0.02 (2%) and 0.18
(18%), and the cumulative plot for the representative recording
from wild-type mice is shown in Fig. 5C. However, the
amplitude changes were not consistent: in five cells the amplitude of mIPSCs was slightly smaller after the application of
CP-93,129, but the amplitudes were larger in the remaining
three cells. Overall, the amplitude was 31.1 ⫾ 6.2 pA in the
control period compared with 32.9 ⫾ 6.8 pA during exposure
to the 5-HT1B receptor agonist. In the eight cells tested,
CP-93,129 decreased the frequency (but not the amplitude) of
mIPSCs by an overall average of 30% (P ⫽ 0.01, paired t-test),
as summarized in Fig. 8B.
FIG. 4. CP-93,129 reduced the frequency but not the amplitude of GABAAreceptor-mediated mIPSCs in the wild-type mouse SCN. Top: a 30-min
recording of mIPSCs. The mIPSCs were pharmacologically isolated by bathing
the slice in AP5 (50 M), DNQX (10 M), and TTX (1 M). Records A–C
(2 s in duration) are expanded from within the boxed portions of the top. A:
control period before application of CP-93,129, all currents are mIPSCs. B:
bath application of CP-93,129 (1 M) reduced the frequency but not the
amplitude of mIPSCs. C: during washout of CP-93,129, there was a partial
recovery of mIPSC frequency to baseline values.

slices prepared from wild-type mice, the effect of CP-93,129
was tested on eight cells. Of the eight cells tested, three showed
a large reduction in mIPSC frequency in response to CP93,129 application. In the control period, the frequency of
mIPSCs was 2.3 ⫾ 0.5 Hz compared with 1.1 ⫾ 0.4 Hz during
drug exposure, reflecting a 52% reduction. A representative
recording from a cell within this group is shown in Fig. 4. An

Effects of CP-93,129 application in the 5-HT1B KO mouse
There was a negligible effect of CP-93,129 application when
tested on slices from four 5-HT1B KO animals; one cell was
recorded from each animal. In the control period, the frequency
of mIPSCs was 2.5 ⫾ 0.5 Hz and the amplitude was 17.8 ⫾ 4.1
pA compared with 2.4 ⫾ 0.5 Hz and 14 ⫾ 3.6 pA during drug
exposure. A representative recording of an SCN neuron from a
5-HT1B KO mouse is shown in Fig. 6, and data for all four cells
are summarized in Fig. 8C; the change in amplitude was not
found to be significant (P ⫽ 0.2). The D values from the
cumulative plots ranged from 0.1 to 0.2 (Fig. 7), and as with
the wild-type mice, the change in mIPSC amplitude was not
consistently in one direction (i.e., 50% of the cells showed a
small increase in mIPSC amplitude after exposure to CP-

FIG. 5. Analysis of mIPSC frequency and amplitude
recorded from a wild-type mouse SCN neuron. A: the
frequency histogram shows a decrease in mIPSC frequency in response to CP-93,129 that partially recovered
during the washout period. B: the amplitude histogram
clearly shows a lack of effect of the 5-HT1B agonist on
mIPSC amplitude. Bin size ⫽ 120 s and error bars
represent the SE. C: the cumulative plot shows a slight
decrease (13%) in the amplitude of mIPSCs after application of CP-93,129 (P ⫽ 0.04). D: the amplitude distributions are similar for control and CP-93,129, although
the significant decrease in the number of events in each
bin reflects the effect on the frequency of mIPSCs (bin
size ⫽ 10 s).
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DISCUSSION

FIG. 6. CP-93,129 had a negligible effect on the frequency and amplitude
of GABAA-receptor-mediated mIPSCs in the 5-HT1B KO mouse SCN. Top: a
30-min recording of mIPSCs. The mIPSCs were pharmacologically isolated by
bathing the slice in AP5 (50 M), DNQX (10 M), and TTX (1 M). Records
A–C (2 s in duration) are expanded from within the boxed portions of the top.
A: baseline before application of CP-93,129; all currents were mIPSCs. B: bath
application of CP-93,129 (1 M) had no effect on the frequency or the
amplitude of mIPSCs. C: washout of CP-93,129.

93,129 and 2 cells showed a decrease in amplitude. The effect
of CP-93,129 on the frequency of mIPSCs in six of eight cells
from wild-type mice was significantly different from the response to CP-93,129 on the frequency of mIPSCs in cells from
5-HT1B KO mice (0 of 4 cells; P ⫽ 0.03, Fisher’s exact test,
1-tailed).

The present study demonstrates that 5-HT1B receptors are
located presynaptically on GABA terminals in the rodent SCN
and that activation of these receptors in vitro decreases the
release of GABA from these terminals. The highly selective
5-HT1B agonist CP-93,129 (Koe et al. 1992a) reduced the
frequency but not the amplitude of GABAergic mIPSCs in the
majority of cells tested from animals with functional 5-HT1B
receptors, indicating a presynaptic site of action. This finding is
consistent with the location of this receptor in the CNS predominately on axon terminals (Boschert et al. 1994) and
numerous reports demonstrating 5-HT1B receptor-mediated
presynaptic inhibition of transmitter release in several different
regions of the CNS (Berger and Huynh 2002; Mlinar et al.
2003; Mooney et al. 1994; Pickard et al. 1999; Singer et al.
1996; Smith et al. 2001; Stanford and Lacey 1996; Tanaka and
North 1993).
The location of the cell bodies that give rise to the GABAergic axon terminals examined in this study is not known with
certainty. GABA terminals in the SCN are known to arise from
several sources, including GABAergic neurons in the IGL that
project to the SCN via the GHT (Morin 1994). However, most
GABAergic axonal boutons in the SCN originate from the
extensive GABAergic local network in the SCN (Castel and
Morris 2000; Strecker et al. 1997; van den Pol 1986). 5-HT1B
mRNA has been reported in the SCN (Roca et al. 1993),
consistent with a local site of receptor synthesis. Manrique and
colleagues (1999) have provided indirect evidence for 5-HT1B
binding sites associated with GHT terminals in the SCN. It
may well be the case that not all GABAergic terminals within
the SCN express the 5HT1B receptor. This would explain the
lack of effect of CP-93,129 on some of the cells recorded, and
because we were not able to determine the source of the
GABAergic terminals in these experiments, it is difficult to
separate the cells into different groups without additional
characterization of the recorded cells. Experiments using pro-

FIG. 7. Analysis of mIPSCs recorded from the KO
mouse. A and B: the frequency and amplitude histograms
for this recording show a lack of effect of CP-93,129 on
mIPSCs (bin size ⫽ 120 s and the error bars represent the
SE). C: the cumulative plot shows a slight decrease (10%)
in the amplitude of mIPSCs after application of CP-93,129.
D: the amplitude distributions are similar for control and
CP-93,129 (bin size ⫽ 10 s).
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cedures similar to those described in the current study conducted in animals in which the IGL has been ablated may help
to resolve this issue.
Although the polar character of CP-93,129 is apparently the
reason, it has very low penetrability into the CNS, it is also
probably responsible for its selective affinity at 5-HT1B receptors (Koe et al. 1992b). Indeed, at a concentration (1 M)
shown to be maximally effective at inhibiting transmitter
release in vitro in previous studies (Berger and Huynh 2002;
Mlinar et al. 2003; Singer et al. 1996), CP-93,129 was ineffective in altering the frequency of mIPSCs in mice lacking
functional 5-HT1B receptors. The variability in mIPSC frequency between successive 120-s bins during the baseline
period in all recordings was ⬃8.9 ⫾ 1.1%, so the change of
ⱕ7% that was seen in KO animals is within the inherent
variability in the system; therefore CP-93,129 showed negligible effects in the 5-HT1B KO mice. The mIPSC amplitude also
varied (6.4 ⫾ 1.3%) between successive 120-s bins during the
baseline period. We have shown in previous studies that
5-HT1B KO mice serve as excellent pharmacological controls
for examining the specificity of 5-HT1B receptor agonists both
in vivo and in vitro (Pickard et al. 1999; Smith et al. 2001).
Taken together, these data support the interpretation that the
response of the 5-HT1B agonist used in rats and wild-type mice
was due to the activation of 5-HT1B receptors (Fig. 8).

Previous work has shown that 5-HT1B receptors on retinal
terminals act to inhibit the response of SCN neurons to light
stimulation (Pickard et al. 1999; Smith et al. 2001). Thus one
might expect that in the 5-HT1B KO mouse there would be an
enhanced response of the circadian system to light stimulation.
However, this is apparently not the case, as behavioral studies
indicate that 5-HT1B KO animals actually exhibit an attenuated
response to photic stimulation (Ogilvie et al. 2004). The
relative number of GABA terminals in the SCN far outweighs
the number of glutamatergic retinal terminals in the SCN, so
even with the removal of 5-HT1B inhibition on glutamate
release from the retinal terminals, the lack of inhibition of
GABA release may have a much greater total effect with an
outcome of an attenuated response to light stimulation. It is not
understood at present how increased SCN GABA release in
5-HT1B KO mice may alter the response of the SCN circadian
system to light. It is possible that excessive GABA release
activates GABAB receptors that are located on RHT terminals
(Jiang et al. 1995). Additional work is clearly necessary to
reveal the underlying physiological mechanisms responsible
for the attenuated response of 5-HT1B KO animals to light.
The relationship between 5-HT and GABA terminals in the
SCN has long been recognized. Bosler (1989) described extensive axo-axonal interactions between 5-HT and GABA
terminals in the SCN and suggested that “every 5-HT varicos-

FIG. 8. Frequency and amplitude histograms of the collective data from experiments in the rat, wild-type mouse, and
5-HT1B KO mouse summarize the effects of CP-93,129. A and
B: CP-93,129 reduced the frequency of mIPSCs by 22% (P ⫽
0.03) and 30% (P ⫽ 0.01) in the rat and mouse, respectively,
when considering all cells recorded as a single population,
suggestive of a presynaptic action of CP-93,129. The bars to the
right of the dashed line in each histogram show the results when
the population is divided into cells that show a strong, subtle or
lack of effect to CP-93,129. There were no significant changes
in the amplitude of mIPSCs. C: CP-93,129 had no effect on the
frequency of mIPSCs in all cells recorded from the KO mouse
and the change in mIPSC amplitude was not significant (P ⫽
0.2). The numbers of neurons tested are represented by (n), and
only one neuron was recorded from each slice preparation.
Error bars represent the SE.
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ity in the SCN might well be apposed to at least one GABA
terminal.” Indirect evidence from circadian behavioral studies
(Mintz et al. 1997) and 5-HT-induced Ca⫹2 transients in the
SCN (Flett and Colwell 1999) suggests that 5-HT can act
within the SCN to alter GABA activity. Jiang and colleagues
(2000) provide evidence from SCN neurons in hypothalamic
slices that 5-HT can alter GABA release via a presynaptic
mechanism (in 3 of 10 cells); although the 5-HT receptor
subtype mediating this response was not specified. 5-HT7
receptors have been described on GABA terminals in the SCN
(Belenky and Pickard 2001) and the current study also supports
the localization of 5-HT1B receptors on GABA terminals in the
SCN. Indeed, the presynaptic interactions between 5-HT and
GABA may well be wide spread throughout the CNS (Belenky
and Pickard 2001; Johnson et al. 1992; Matsuoka et al. 2004;
Stanford and Lacey 1996; van Bockstaele et al. 1996; Yan and
Yan 2001).
In summary, the present study provides data from SCN
neurons in hypothalamic slices from rat and mouse indicating
that 5-HT1B receptors are located presynaptically on GABA
axonal terminals and that activation of these receptors inhibits
GABA release.
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